Please select the option that best describes you:
How do you use neratinib in HR+ HER2+ patients in the adjuvant setting if patients got adjuvant T-DM1 for residual disease after neoadjuvant therapy?
Neratinib was studied following adjuvant trastuzumab. Do you extrapolate that data to give neratinib to patients who have received adjuvant T-DM1 instead of trastuzumab?
Answer from: Medical Oncologist at Academic Institution
I do not routinely apply neratinib. I base the decision on my best estimate of two factors:
The obvious issues with neratinib toxicity
The residual risk that the patient has after TDM1. Not all residual disease patients are equal. I would approach a patient with a minimal respo...
Sign in or Register to read more